Xeikon to Highlight the Xeikon 8000 Digital Color Press
ITASCA, IL—09/08/2009—Xeikon (www.xeikon.com), a division of Punch Graphix, legendary for pioneering the first digital color presses, today announced that the company will be exhibiting at the upcoming PRINT 09 event, one of the largest and most comprehensive global graphic communications exhibitions, taking place in Chicago, September 11-16, 2009.
At the event Xeikon will be demonstrating the Xeikon 8000, the company’s flagship digital color press at booth #2529, as well as featuring a dedicated label and packaging area. This label and packaging space will be complete with high impact samples produced on its award winning Xeikon 3300 digital color press.
The Xeikon 8000’s high-precision LED-based imaging head features true 1200 dpi resolution and 1200 x 3600 dpi addressability with variable dot density, generating extraordinary image quality with sharp and crisp details, high definition, and smooth tone transitions. The new imaging technology makes use of the powerful Pericles screening library, allowing screen rulings up to 240 lpi, further optimizing overall image quality. Two in-line densitometers and high-performance process algorithms provide uniform and accurate colors and perfect color registration, guaranteeing color consistency from job to job and from press to press. Specially developed Xeikon Productivity Adapted (PA) toner supports cost-effective impeccable print quality at high speeds. Web-fed, it prints full color multi-page documents at a top speed of 244 letter-size pages per minute and its exceptional uptime enables duty cycles of up to 9.0 million letter-size pages per month.
“Xeikon is thrilled to participate at the upcoming PRINT 09 conference, and we truly see the value of having a significant presence at this event,” said Bram Bourgeois, President and CEO of Punch Graphix Americas, Inc. “We are looking forward to demonstrating the industry-leading capabilities of the Xeikon 8000, as well as discussing our recent corporate partnership with Dana-Farber Cancer Institute and the Jimmy Fund.”